Isis Books Kynamro Milestone; Seeks Partners For Other Pipeline Assets
The focus at Isis turns to the near-term prospects of an approval for the cholesterol drug Kynamro and to business development.
The focus at Isis turns to the near-term prospects of an approval for the cholesterol drug Kynamro and to business development.